Zydus Cadila gets USFDA nod to market blood pressure lowering drug in the US

Drug firm Zydus Cadila on Tuesday said it has received final approval from the US health regulator to market Atenolol and Chlorthalidone tablets USP, used to treat high blood pressure, in the US

Press Trust of India March 12, 2019 15:42:05 IST
Zydus Cadila gets USFDA nod to market blood pressure lowering drug in the US
  • Zydus Cadila said it has received final approval from the USFDA to market Atenolol and Chlorthalidone tablets USP, used to treat high blood pressure, in the US

  • It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad

  • Shares of Cadila Healthcare, the listed entity of the group, was trading at Rs 336.90 per scrip, up 1.26 percent on BSE

New Delhi: Drug firm Zydus Cadila on Tuesday said it has received final approval from the US health regulator to market Atenolol and Chlorthalidone tablets USP, used to treat high blood pressure, in the US.

The company has received approval from the US Food and Drug Administration (USFDA) to market the medication in two different strengths, Zydus Cadila said in a statement.

Zydus Cadila gets USFDA nod to market blood pressure lowering drug in the US

Representational image. Getty.

It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

Atenolol belongs to a class of drugs known as beta blockers. It works by blocking the action of certain natural chemicals in the body, such as epinephrine on the heart and blood vessels.

Chlorthalidone is a ‘water pill' (diuretic) and causes the body to get rid of extra salt and water.

The Zydus group now has 253 product approvals since the commencement of the filing process in 2003-04.

Shares of Cadila Healthcare, the listed entity of the group, was trading at Rs 336.90 per scrip, up 1.26 percent on BSE.

Updated Date:

also read

Cipla submits application with USFDA for generic version of asthma drug
Business

Cipla submits application with USFDA for generic version of asthma drug

Drug major Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, which is used in the treatment of asthma and other respiratory disorders

Pharma major Lupin’s Aurangabad facility gets Establishment Inspection Report from USFDA
India

Pharma major Lupin’s Aurangabad facility gets Establishment Inspection Report from USFDA

Pharma major Lupin has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Aurangabad facility.

After Ranbaxy saga, USFDA gets cracking on drug facilities in India
Business

After Ranbaxy saga, USFDA gets cracking on drug facilities in India

The US health regulator, which has been cracking the whip against many Indian pharmaceutical firms, including Ranbaxy Laboratories and Wockhardt, is also recruiting and training additional drugs investigators in India.<br /><br />